Sign up to access all valuation multiples
HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.
2007
699
LTM Revenue $173M
LTM EBITDA -$46.8M
$2.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of December 2025, HeartFlow reported last 12-month revenue of $173M and EBITDA of -$46.8M.
In the same period, HeartFlow generated $132M in LTM gross profit and -$101M in net income.
See HeartFlow valuation multiples based on analyst estimatesIn the most recent fiscal year, HeartFlow reported revenue of $126M and EBITDA of -$65.5M.
HeartFlow expects next 12-month revenue of XXX and NTM EBITDA of XXX
See HeartFlow valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $173M | XXX | $126M | XXX | XXX | XXX |
| Gross Profit | $132M | XXX | $94.4M | XXX | XXX | XXX |
| Gross Margin | 76% | XXX | 75% | XXX | XXX | XXX |
| EBITDA | -$46.8M | XXX | -$65.5M | XXX | XXX | XXX |
| EBITDA Margin | -27% | XXX | -52% | XXX | XXX | XXX |
| EBIT | -$52.3M | XXX | -$61.2M | XXX | XXX | XXX |
| EBIT Margin | -30% | XXX | -49% | XXX | XXX | XXX |
| Net Profit | -$101M | XXX | -$96.4M | XXX | XXX | XXX |
| Net Margin | -58% | XXX | -77% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $85.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
HeartFlow has current market cap of $3.2B, and EV of $2.9B.
As of January 19, 2026, HeartFlow's stock price is $37.
See HeartFlow trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.9B | $3.2B | XXX | XXX | XXX | XXX | $-1.95 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialHeartFlow's trades at 16.7x EV/Revenue multiple, and -61.9x EV/EBITDA.
See valuation multiples for HeartFlow and 15K+ public compsAs of January 19, 2026, HeartFlow has market cap of $3.2B and EV of $2.9B.
Equity research analysts estimate HeartFlow's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
HeartFlow has a P/E ratio of -31.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.2B | XXX | $3.2B | XXX | XXX | XXX |
| EV (current) | $2.9B | XXX | $2.9B | XXX | XXX | XXX |
| EV/Revenue | 16.7x | XXX | 16.7x | XXX | XXX | XXX |
| EV/EBITDA | -61.9x | XXX | -61.9x | XXX | XXX | XXX |
| EV/EBIT | -55.4x | XXX | -55.4x | XXX | XXX | XXX |
| EV/Gross Profit | 22.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -31.4x | XXX | -31.4x | XXX | XXX | XXX |
| EV/FCF | -55.7x | XXX | -55.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHeartFlow's last 12 month revenue growth is 22%
HeartFlow's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
HeartFlow's rule of 40 is -50% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
HeartFlow's rule of X is 29% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for HeartFlow and other 15K+ public comps| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 22% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Margin | -27% | XXX | -27% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -50% | XXX | -5% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 29% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 35% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 124% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
HeartFlow acquired XXX companies to date.
Last acquisition by HeartFlow was XXXXXXXX, XXXXX XXXXX XXXXXX . HeartFlow acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was HeartFlow founded? | HeartFlow was founded in 2007. |
| Where is HeartFlow headquartered? | HeartFlow is headquartered in United States of America. |
| How many employees does HeartFlow have? | As of today, HeartFlow has 699 employees. |
| Who is the CEO of HeartFlow? | HeartFlow's CEO is Mr. John C.M. Farquhar. |
| Is HeartFlow publicy listed? | Yes, HeartFlow is a public company listed on NAS. |
| What is the stock symbol of HeartFlow? | HeartFlow trades under HTFL ticker. |
| When did HeartFlow go public? | HeartFlow went public in 2025. |
| Who are competitors of HeartFlow? | Similar companies to HeartFlow include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of HeartFlow? | HeartFlow's current market cap is $3.2B |
| What is the current revenue of HeartFlow? | HeartFlow's last 12 months revenue is $173M. |
| What is the current revenue growth of HeartFlow? | HeartFlow revenue growth (NTM/LTM) is 22%. |
| What is the current EV/Revenue multiple of HeartFlow? | Current revenue multiple of HeartFlow is 16.7x. |
| Is HeartFlow profitable? | Yes, HeartFlow is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of HeartFlow? | HeartFlow's last 12 months EBITDA is -$46.8M. |
| What is HeartFlow's EBITDA margin? | HeartFlow's last 12 months EBITDA margin is -27%. |
| What is the current EV/EBITDA multiple of HeartFlow? | Current EBITDA multiple of HeartFlow is -61.9x. |
| What is the current FCF of HeartFlow? | HeartFlow's last 12 months FCF is -$52.0M. |
| What is HeartFlow's FCF margin? | HeartFlow's last 12 months FCF margin is -30%. |
| What is the current EV/FCF multiple of HeartFlow? | Current FCF multiple of HeartFlow is -55.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
